Literature DB >> 8393295

Actions of Helodermatidae venom peptides and mammalian glucagon-like peptides on gastric chief cells.

A Rai1, G Singh, R Raffaniello, J Eng, J P Raufman.   

Abstract

The actions of peptides (helospectin I, helodermin, exendin-3, exendin-4) that have been isolated from the venoms of Helodermatidae lizards were examined using dispersed chief cells from guinea pig stomach. These actions were compared with those of mammalian glucagon-like peptides, particularly truncated glucagon-like peptide 1 (TGLP-1), a peptide that shares 53% homology with exendin-4. The Helodermatidae venom peptides and TGLP-1 caused a two- to threefold increase in chief cell adenosine 3',5'-cyclic monophosphate and pepsinogen secretion. Exendin-3 and exendin-4 were 100 times more potent than helospectin I and helodermin and 10 times more potent than TGLP-1. Helospectin I and helodermin, but not exendin-4 or TGLP-1, inhibited the binding of 125I-labeled vasoactive intestinal peptide (VIP) and 125I-secretin to dispersed chief cells. The actions of exendin-3, exendin-4, and TGLP-1, but not those of helospectin I, helodermin, VIP, or secretin, were progressively inhibited by increasing concentrations of an exendin-receptor antagonist, exendin-(9-39)-NH2. These data indicate that in gastric chief cells, whereas the actions of helospectin I and helodermin are mediated by interaction with high-affinity secretin (low-affinity VIP) receptors, the actions of exendin-3, exendin-4, and TGLP-1 are mediated by interaction with exendin receptors.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8393295     DOI: 10.1152/ajpgi.1993.265.1.G118

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  2 in total

1.  Inhibition of human gastric lipase secretion by glucagon-like peptide-1.

Authors:  M Wøjdemann; A Wettergren; B Sternby; J J Holst; S Larsen; J F Rehfeld; O Olsen
Journal:  Dig Dis Sci       Date:  1998-04       Impact factor: 3.199

2.  Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.

Authors:  J Schirra; K Sturm; P Leicht; R Arnold; B Göke; M Katschinski
Journal:  J Clin Invest       Date:  1998-04-01       Impact factor: 14.808

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.